Eli Lilly's weight-loss drug Mounjaro is being recommended for some UK patients with obesity by Britain's medical costs regulator. This draft guidance could lead to the NHS offering Mounjaro for free as an alternative to Novo Nordisk's Wegovy on better terms. Unlike Wegovy, the regulator suggests not placing a time limit on Mounjaro's use. The recommendation comes a year after the spending watchdog initially refused to approve Mounjaro.
Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for rival Novo Nordisk's Wegovy. https://t.co/TDvjlGac2g https://t.co/TDvjlGac2g
Britain considers offering Lilly weight-loss drug on better terms than Wegovy https://t.co/HMBl0VTK0j https://t.co/CYa6iFGnDv
Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for rival Novo Nordisk's Wegovy. https://t.co/oSGN7zzFrr https://t.co/oSGN7zzFrr
'King Kong' weight loss jab set to be free on the NHS: spending watchdog gives green light to powerful new drug Mounjaro, a year after refusing to approve it https://t.co/JRcgwQnVa8 https://t.co/Rr6ojkZbNJ
Eli Lilly’s Mounjaro is being recommended for weight loss for some UK patients with obesity, in draft guidance that could see the NHS offer a rival drug to Novo Nordisk's hit treatment Wegovy https://t.co/LWOD6sdL0J